25 November 2022 - Application includes important pivotal Phase 3 data evaluating the efficacy and safety of our vaccine candidate against respiratory syncytial virus-lower respiratory tract disease in adults aged 60 years and above.
GSK has filed a new drug submission to Health Canada for its respiratory syncytial virus older adult vaccine candidate.